The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
Glennys Sanders House
Sleaford, NG34 8GL United Kingdom
Guillain-Barré syndrome, also known as AIDP, is an acute auto-immune condition affecting the peripheral nerves, in which the body’s immune system attacks the myelin sheath (insulating coating of the nerves). This leads to the short-circuiting of the nerve signals which causes sudden weakness resulting in paralysis and a loss of sensation, often but not always with severe pain. The worst degree of weakness is usually reached within 4 weeks and always within 6 weeks. Recovery can take a few weeks or many months. What we do: -Help people understand and manage GBS, CIDP and the associated variants -Promote and facilitate both clinical and non-clinical research -Raise awareness of the charity and conditions
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.